A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient
This research summary focuses on analyzing how oligonucleotide/ RNA size and the types of lipids used influence the key properties of lipid nanoparticles synthesized via microfluidic techniques.
The peer-reviewed article “A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient” was originally published in Scientific Reports, in 2024 by Gretchen B. Schober, Sandra Story and Dev P. Arya from NUBAD LLC / Clemson University.
Abstract
In the wake of the COVID-19 vaccine success, the use of lipid nanoparticles, or LNP, for RNA delivery has been brought to the spotlight. LNPs, as non-viral carriers, are vital for protecting and delivering RNA therapeutics, which are otherwise fragile and prone to degradation. Despite the success of FDA-approved formulations for mRNA delivery, there is still a need for better understanding and refining these benchmark lipid formulations to both improve their efficiency and adapt them to other cargos. This study aims to enhance the understanding and application of LNP-based RNA delivery systems by investigating the impact of various lipid compositions and RNA cargo size, on the encapsulation efficiency and final size of RNA-LNPs. This analysis has been conducted under uniform conditions by using microfluidics, to focus specifically on the interactions between lipid mixtures and RNA types.
Introduction: impact of RNA size on LNP characteristics
Lipid nanoparticles (LNPs) have emerged as effective carriers for therapeutic nucleic acids, with several formulations approved by the FDA. These LNPs are designed to address the challenges of delivering unprotected nucleic acids, such as susceptibility to biological degradation and difficulty in crossing cellular barriers.
A variety of RNA types are selected for this study, including antisense oligonucleotides (ASO), small interfering RNA (siRNA), RNA aptamers, and messenger RNA (mRNA), reflecting the diverse applications and potential of RNA-based therapies.
Additionally, the composition of LNPs, which is critical for their function, typically involves 4 components: ionizable lipids, helper phospholipids, cholesterol, and polyethylene glycol (PEG)-lipids. The ionizable lipid structure, particularly its impact on RNA encapsulation and delivery, makes it a key area of research and a significant battleground for intellectual property.
In this study, the production of lipid nanoparticles (LNPs) was made using the cutting-edge microfluidic self-assembly process. This method stands out for its ability to produce highly uniform nanoparticles, achieving optimal encapsulation efficiency, precise control and repeatability. Such approach enables a robust correlation between inputs, like cargo size and lipid mix, and outputs, including RNA-LNP size, Polydispersity Index (PDI), Encapsulation Efficiency (EE%), enhancing the effectiveness of the LNPs produced.
Goals of the study:
- Comparing the influence of the Lipid Mix and the cargo size on the final nanoparticle size, PDI, and encapsulation efficiency.
- Evaluating the relevance of using EEinput% rather than EE% for the actual encapsulation efficiency measurement
Experimental Setup: Lipid mix, Cargo, and characterization
In this study, LNPs were prepared using microfluidic methods, involving herringbone mixers using a 60:1 lipid to RNA ratio.
4 LNP formulations were evaluated with the same molar ratio of 50:10:38.5:1.5 respectively of ionizable lipid (DLin-MC3-DMA or ALC-0315), phospholipid (DSPC or DOPE), structural lipid (cholesterol) and helper lipid (DMG-PEG2000).
Each of the lipid formulations was tested with 5 different oligonucleotides of different lengths including ASO (10 bases), siRNA( 21 base pairs), aptamer (96 bases), and mRNA strands of different lengths (996 bases and 1929 bases).
RNA-LNP complexes were characterized using standard methods including RiboGreen Encapsulation efficiency measurement, and Size and PDI measurements were carried out using DLS.
Key findings: LNP EE% vs EEinput% and lipid nanoparticle size
LNP Encapsulation efficiency:
The study further explores the encapsulation efficiency (EE) of lipid nanoparticles (LNPs), examining it through two different calculation methods:
- The standard EE% method, calculates the ratio of encapsulated RNA to total RNA present in the sample at the end of the production process,
- The EEinput% method, which considers the concentration of input RNA, alongside the encapsulated RNA.
Comparing these 2 approaches, the study shows that actual RNA encapsulation is often lower than reported. This discrepancy suggests that a substantial portion of the input RNA is unaccounted for in the final product, likely due to degradation of the RNA during the process. These degradation mechanisms will artificially increase the EE% by decreasing the unencapsulated RNA concentration.
The paper also points out that larger RNA molecules are encapsulated more effectively in lipid nanoparticles (LNPs) than smaller RNA molecules. This enhanced efficiency is likely due to the stronger electrostatic interactions between the larger RNA and the ionizable lipids in the LNPs. Additionally, the lipid mix also appears to have an impact on the encapsulation efficiency.
These findings underscore the importance of refining LNP formulations, particularly for therapeutic applications, and highlight the importance of accounting for input RNA concentration in encapsulation efficiency evaluations.
Finally, a follow-up study examined the discrepancy between EE% and EEinput% for mRNA with different total lipid concentrations while maintaining a constant RNA-to-ionizable lipid ratio. Results showed that increasing lipid concentration significantly improved EEinput%, highlighting the need to consider input RNA concentration in efficiency calculations. This approach provides more accurate insights into reaction efficiency and aids in optimizing LNP formulations.
Lipid nanoparticle size:
The size analysis showed no clear link between RNA size and LNP diameter in the regime of high lipid excess. This observation is in line with other research which indicates that LNP size depends more on lipid concentration, mixing conditions, and PEG-lipid concentration, rather than the RNA size itself. It was thought that different RNA sizes might affect LNP size due to the varying arrangements of lipids and RNA within the particles, yet it appears not to be the case. However, morphology and internal LNP organization such as packing efficiency might vary and should be further studied.
Conclusion: standard encapsulation efficiency can be deceptive; lipid nanoparticle size unaffected by RNA size, yet different formulations are needed for varying RNA sizes
In summary, the study highlights the critical role of lipid nanoparticles (LNPs) in RNA therapeutic delivery, safeguarding the RNA from degradation. In an analysis exploring the encapsulation efficiency of various RNA cargo sizes, the study unveils an intriguing fact: the traditional methods of calculating encapsulation efficiency often overstate their actual efficiency. It suggests that the concentration of RNA should be factored into efficiency assessments, and alternate methods like EEinput% might offer more accurate encapsulation characterization.
Interestingly, the research indicates that the same formulations yielding positive results for smaller RNA types, like siRNA, may not be as effective for larger RNA types, such as mRNA. This necessitates tailored adjustments in the formulation process depending on the RNA size.
Contrary to expectations, the study finds that the size of LNPs isn't significantly influenced by the size of the RNA cargo. Instead, the findings point out that the size is largely determined by the specific conditions of the reaction, including the lipid mix, ratio, and microfluidic mixing parameters, rather than the RNA cargo size itself.
In conclusion, this research demonstrates that the LNP formulation plays a more significant role in determining the final characteristics of RNA-LNPs than the RNA cargo itself. Thus, while the formulations should be optimized according to the specific RNA cargo, the overarching influence lies in the formulation conditions themselves.
Looking for a microfluidic system to formulate lipid nanoparticles ?
Reach out to us
Reference:
Schober, G.B., Story, S. & Arya, D.P. A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient. Sci Rep 14, 2403 (2024). https://doi.org/10.1038/s41598-024-52685-1